# Ronald Hunt

> Ronald Hunt is a Series B investor at New Leaf Venture Partners backing Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners)
- Location: New York, United States
- Total investments: 5
- Last investment: Oct 2023
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ron-hunt-144595a1/

Ronald Hunt is a Series B investor at New Leaf Venture Partners in New York focused on Health Care and Therapeutics. Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Ron was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Prior to joining Sprout in early 1998, Ron was a consultantwith the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (M.B.A.) and Cornell University (B.S.).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Medical Device | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| Ireland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Harpoon Therapeutics | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $100M | Post-IPO Equity | Oct 23, 2023 |  |
| Harpoon Therapeutics | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $70M | Series C | Nov 12, 2018 |  |
| Harpoon Therapeutics | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $45M | Series B | May 25, 2017 |  |
| Iterum Therapeutics | Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novelanti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. | $40M | Series A | Mar 24, 2016 |  |
| Stromedix | Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. |  | Series B |  |  |

5 of 5 investments shown.

## Co-investors
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 2 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 1 deal together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together

## About New Leaf Venture Partners

VC Fund · New York, United States

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

5 contacts available at New Leaf Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Craig Slutzkin | CFO & COO | https://shizune.co/investors/profile/craig-slutzkin |
| James Niedel | Managing Director | https://shizune.co/investors/profile/james-niedel |
| Liam Ratcliffe | Managing Director | https://shizune.co/investors/profile/liam-ratcliffe |
| Ronald Hunt | Managing Director | https://shizune.co/investors/profile/ron-hunt-2 |
| Vijay Lathi | Managing Director | https://shizune.co/investors/profile/vijay-lathi |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ronald Hunt invest in?

Ronald Hunt invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ronald Hunt last invest?

The most recent investment recorded for Ronald Hunt closed in Oct 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co